110
Views
4
CrossRef citations to date
0
Altmetric
Review

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women

Pages 127-137 | Published online: 20 Oct 2011

References

  • VogelVGManaging the risk of breast cancer in postmenopausal women: introductionMenopause2008154 Suppl77978118596598
  • GierachGVogelVGEpidemiology of breast cancerSingletarySERobbGLHortobagyiGNAdvanced Therapy of Breast Disease2nd edHamilton, ONBC Decker, Inc20045883
  • ReevesKHudsonAVogelVGEpidemiology of breast cancerBlandKICopelandEMThe Breast: Comprehensive Management of Benign and Malignant Disease4th edPhiladelphia, PAElsevier2009349369
  • VelieEMNechutaSOsuchJRLifetime reproductive and anthropometric risk factors for breast cancer in postmenopausal womenBreast Dis200524173516917137
  • SantenRJManselRBenign breast disordersN Engl J Med200535327528516034013
  • HartmannLCSellersTAFrostMHBenign breast disease and the risk of breast cancerN Engl J Med200535322923716034008
  • ClausEBRischNThompsonWDGenetic analysis of breast cancer in the Cancer and Steroid Hormone StudyAm J Hum Genet1991482322421990835
  • NarodSAOffitKHereditary breast cancer: prevention and management of hereditary breast cancerJ Clin Oncol2005231656166315755973
  • GailMHBrintonLAByarDPProjecting individualized probabilities of developing breast cancer for white females who are being examined annuallyJ Natl Cancer Inst198981187918862593165
  • CostantinoJPGailMHPeeDValidation studies for models projecting the risk of invasive and total breast cancer incidenceJ Natl Cancer Inst1999911541154810491430
  • BarlowWEWhiteEBallard-BarbashRProspective breast cancer risk prediction model for women undergoing screening mammographyJ Natl Cancer Inst2006981204121416954473
  • ChlebowskiRTAndersonGLLaneDSWomen’s Health Initiative Investigators. Predicting risk of breast cancer in postmenopausal women by hormone receptorJ Natl Cancer Inst2007991695170518000216
  • CummingsSRTiceJABauerSPrevention of breast cancer in postmenopausal women: approaches to estimating and reducing riskJ Natl Cancer Inst200910138439819276457
  • TiceJACummingsSRZivEKerlikowskeKMammographic breast density and the Gail model for breast cancer risk prediction in a screening populationBreast Cancer Res Treat20059411512216261410
  • BoydNFMartinLJYaffeMJMinkinSMammographic density: a hormonally responsive risk factor for breast cancerJ Br Menopause Soc20061218619317178021
  • KerlikowskeKIchikawaLMigliorettiDLNational Institutes of Health Breast Cancer Surveillance ConsortiumLongitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer riskJ Natl Cancer Inst20079938639517341730
  • ChenJPeeDAyyagariRProjecting absolute invasive breast cancer risk in white women with a model that includes mammographic densityJ Natl Cancer Inst2006981215122616954474
  • CuzickJPowlesTVeronesiUOverview of the main outcomes in breast-cancer prevention trialsLancet200336129630012559863
  • FisherBCostantinoJPWickerhamDLTamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJ Natl Cancer Inst199890137113889747868
  • FisherBCostantinoJPWickerhamDLTamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1studyJ Natl Cancer Inst2005971652166216288118
  • VeronesiUMaisonneuvePSacchiniVRotmenszNBoylePItalian Tamoxifen Study GroupTamoxifen for breast cancer among hysterectomised womenLancet20023591122112411943263
  • VeronesiUMaisonneuvePRotmenszNItalian Tamoxifen Study GroupItalian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk womenJ Natl Cancer Inst20039516016512529349
  • VeronesiUMaisonneuvePRotmenszNItalian Tamoxifen Study GroupTamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomyJ Natl Cancer Inst20079972773717470740
  • CuzickJForbesJEdwardsRIBIS investigatorsFirst results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trialLancet200236081782412243915
  • CuzickJForbesJFSestakIInternational Breast Cancer Intervention Study I InvestigatorsLong-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trialJ Natl Cancer Inst20079927228217312304
  • PowlesTJAshleySTidyASmithIDowsettMTwenty-year follow-up of the Royal Marsden randomized, double-blinded Tamoxifen Breast Cancer Prevention TrialJ Natl Cancer Inst20079928329017312305
  • CummingsSREckertSKruegerKAThe effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trialJAMA19992812189219710376571
  • CauleyJANortonLLippmanMEContinued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluationBreast Cancer Res Treat20016512513411261828
  • MartinoSCauleyJABarrett-ConnorECORE InvestigatorsContinuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifeneJ Natl Cancer Inst2004961751176115572757
  • Barrett-ConnorEMoscaLCollinsPRaloxifene Use for The Heart (RUTH) Trial InvestigatorsEffects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenN Engl J Med200635512513716837676
  • VogelVGCostantinoJPWickerhamDLNational Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialJAMA20062952727274116754727
  • VogelVGCostantinoJPWickerhamDLNational Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancerCancer Prev Res20103696706
  • LandSRWickerhamDLCostantinoJPPatient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trialJAMA20062952742275116754728
  • HortobagyiGNBrownPHTwo good choices to prevent breast cancer: great taste, less fillingCancer Prev Res20103681685
  • VogelVGThe NSABP Study of Tamoxifen and Raloxifene (STAR) TrialExpert Rev Anticancer Ther20099516019105706
  • VisvanathanKChlebowskiRTHurleyPAmerican Society of Clinical OncologyAmerican society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reductionJ Clin Oncol2009273235325819470930
  • VogelVGRaloxifene: a second-generation selective estrogen receptor modulator for reducing the risk of invasive breast cancer in postmenopausal womenWomen’s Health20073139153